IBEX 35
10.854,70 -17,30 (-0,16%) Euro Stoxx 50
4.921,48 +30,87 (+0,63%) Dólar/Euro
1,0765 +0,0038 (+0,36%) Petróleo Brent
82,82 -0,85 (-1,02%) Oro
2.310,10 +0,50 (+0,02%) Bitcoin EUR
59.342,79 +2.067,43 (+3,61%)
Arbutus Biopharma Corporation (ABUS)
Después del cierre:
Arbutus Biopharma Corporation
701 Veterans Circle
Warminster, PA 18974
United States
267 469 0914
https://www.arbutusbio.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 73
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Michael J. McElhaugh | Co-Founder, Interim President, CEO & Director | 644,4k | N/A | 1975 |
| Dr. Michael J. Sofia Ph.D. | Chief Scientific Officer | 656,1k | N/A | 1958 |
| Mr. David C. Hastings CPA | CFO & Chief Accounting Officer | 647,1k | N/A | 1961 |
| Ms. Lisa M. Caperelli | Vice President of Investor Relations | N/A | N/A | N/A |
| Mr. J. Christopher Naftzger BA, Esq., J.D. | General Counsel, Chief Compliance Officer & Secretary | N/A | N/A | 1967 |
| Ms. Shannon Briscoe SPHR | Vice President of Human Resources | N/A | N/A | N/A |
| Dr. Karen Sims M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1971 |
| Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C. | Corporate Secretary | N/A | N/A | 1951 |
Descripción
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Gobierno corporativo
El ISS Governance QualityScore de Arbutus Biopharma Corporation, a día 1 de mayo de 2024, es 5. Las puntuaciones base son Auditoría: 1; Tablero: 5; Derechos de los accionistas: 9; Compensación: 6.
